ClinicalTrials.gg
CompletedNCT03034460Updated Dec 11, 2020Results posted

Efficacy and Safety of CD5024 1% in Acne Vulgaris

A Phase 2 interventional study of CD5024 1% cream and CD5024 cream placebo in Acne, sponsored by Galderma R&D. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2020-12-11.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2016, registered Nov 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Acne Vulgaris by Galderma Group AG — none open to participants now, 1 under way, 1 of them phase 3. Acne Vulgaris · Galderma Group AG.

Enrollment
35th of 46
70 · median 194
Started
2016
with 3 others
Phase 2
5 of 49
none open now
Registered
44th of 49
by date

Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 35th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2016, is one of 5 in phase 2, and was the 44th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 49 studies in Acne Vulgaris by Galderma Group AG is open now. The open studies under Acne Vulgaris, anywhere →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies in Acne Vulgaris by Galderma Group AG as a file.
02

Study summary

Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.

Read the detailed description

Study drugs application will be performed once daily, 5 days a week during 6 weeks

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is a male or a female aged from 18 to 35 years old at screening visit.
  2. The subject has a medical diagnosis of acne vulgaris :

    2.1 at least 20 (twenty) inflammatory lesions and a maximum of 100 (one hundred) non-inflammatory lesions (nose is excluded for the lesion count) at Baseline

    2.2 symmetry of the lesions: No more than twice as many acne lesions on one side as compared to the other side at Baseline

  3. If the subject is a female of , she must agree to use an effective method for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. The subject has an underlying known disease surgical or medical condition, in the opinion of the investigator might interfere with interpretation of the study results or put the subject at risk (e.g., other dermatological diseases affecting the treatment area, such as a dermatitis, eczema, etc., or any uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study, such as a cancer, leukemia or severe hepatic impairment), (Screening).
  2. The subject has acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment.
  3. The subject has a known or suspected allergies or sensitivities to any components of any of the study drugs (see Investigator's Brochure/Product label).
  4. The subject is a male with beard or facial hair, which would interfere with clinical evaluation or clinical procedure (Screening and Baseline).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    CD5024 1% cream

    Active drug;

    Drug: CD5024 1% cream

  • Placebo comparator
    CD5024 cream placebo

    Placebo of active drug;

    Drug: CD5024 cream placebo

  • Other
    CD0271/CD1579 gel

    Positive control;

    Drug: CD0271/CD1579 gel

  • Other
    CD0271/CD1579 gel placebo

    Placebo of positive control;

    Drug: CD0271/CD1579 gel placebo

Interventions

  • 500 µL on half-face, five days a week during 6 weeks

  • DrugCD5024 cream placebo

    500 µL on half-face, five days a week during 6 weeks

  • DrugCD0271/CD1579 gel

    500 µL on half-face, five days a week during 6 weeks

  • DrugCD0271/CD1579 gel placebo

    500 µL on half-face, five days a week during 6 weeks

06

What researchers measure

Primary outcomes

  1. Inflammatory Lesion Count (Papules and Pustules) at Day 40

    Inflammatory lesion count corresponded to the sum of papules and pustules.

    Time frame: Day 40

Secondary outcomes

  1. Inflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1)

    Inflammatory lesion count corresponded to the sum of papules and pustules.

    Time frame: Baseline (Day 1)

  2. Percent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 40

    Inflammatory lesion count corresponded to the sum of papules and pustules.

    Time frame: Baseline (Day 1), and Day 40

  3. Total Lesion Count at Baseline (Day 1) and Day 40

    Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.

    Time frame: Baseline (Day 1), and Day 40

  4. Percent Reduction From Baseline (Day 1) in Total Lesions at Day 40

    Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.

    Time frame: Baseline (Day 1), and Day 40

  5. Non-Inflammatory Lesion Count at Baseline (Day 1) and Day 40

    Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.

    Time frame: Baseline (Day 1), and Day 40

  6. Percent Reduction From Baseline in Non-Inflammatory Lesion at Day 40

    Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.

    Time frame: Baseline (Day 1), and Day 40

  7. Number of Participants Reported for Investigator's Preference on a 5-Point Scale at Day 40

    The Investigator gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.

    Time frame: Day 40

  8. Number of Participants Reported for Participant's Preference on 5-Point Scale at Day 40

    The participants gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.

    Time frame: Day 40

  9. Number of Participants With Adverse Events (AEs)

    AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From start of study up to follow up (Week 7)

  10. Number of Participants Reported Worst Local Tolerability Score on Treated Areas (Face and Ear) From Day 1 to Follow up (Week 7)

    Signs and symptoms of local cutaneous irritation(local tolerability \[erythema, scaling, dryness, stinging/burning, pruritus\]) were evaluated on all treated areas (face and behind ears if applicable) every day from Day 1 up to follow-up (Week 7) using a 4-point scale of None (0), Mild (1), Moderate (2), or Severe (3). Number of participants reported worst local tolerability score on treated areas from Day 1 to follow up (Week 7) was reported.

    Time frame: From Day 1 up Follow up (Week 7)

07

Results

Posted Dec 11, 2020

Participant flow

This study was conducted at six centers in three countries (Germany, France, Canada) between 25 April 2016 (first participant screened) to 02 November 2016 (last participant completed).

Participant flow — Overall Study
MilestoneGroup I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its Vehicle
Started4822
Completed4519
Not completed33
Withdrew: Adverse event01
Withdrew: Withdrawal by subject22
Withdrew: Personal reasons10

Outcome measures

PrimaryInflammatory Lesion Count (Papules and Pustules) at Day 40

Inflammatory lesion count corresponded to the sum of papules and pustules.

Time frame:
Day 40
Reported as:
Mean · lesion count
Inflammatory Lesion Count (Papules and Pustules) at Day 40
lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Inflammatory Lesion Count (Papules and Pustules) at Day 4010.1 ± 5.88.9 ± 5.06.1 ± 4.99.4 ± 5.7
Statistical analysis
  • CD5024 1% Cream vs CD5024 1% Cream Matched Placebo · Wilcoxon rank signed test · p = = 0.158
  • Adapalene Benzoyl Peroxyde vs Adapalene Benzoyl Peroxyde Matched Placebo · Wilcoxon rank signed test · p = = 0.002
SecondaryInflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1)

Inflammatory lesion count corresponded to the sum of papules and pustules.

Time frame:
Baseline (Day 1)
Reported as:
Mean · lesion count
Inflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1)
lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Inflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1)16.5 ± 4.917.5 ± 7.417.6 ± 8.616.6 ± 7.2
SecondaryPercent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 40

Inflammatory lesion count corresponded to the sum of papules and pustules.

Time frame:
Baseline (Day 1), and Day 40
Reported as:
Mean · percent reduction of lesion count
Percent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 40
percent reduction of lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Percent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 4035.7 ± 43.444.4 ± 32.365.5 ± 24.042.5 ± 30.1
SecondaryTotal Lesion Count at Baseline (Day 1) and Day 40

Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.

Time frame:
Baseline (Day 1), and Day 40
Reported as:
Mean · lesion count
Total Lesion Count at Baseline (Day 1) and Day 40
lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Baseline (Day 1)37.7 ± 11.239.4 ± 13.737.3 ± 20.236.4 ± 18.0
Day 4026.4 ± 16.825.9 ± 14.319.3 ± 15.025.5 ± 17.2
SecondaryPercent Reduction From Baseline (Day 1) in Total Lesions at Day 40

Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.

Time frame:
Baseline (Day 1), and Day 40
Reported as:
Mean · percent reduction in total lesion count
Percent Reduction From Baseline (Day 1) in Total Lesions at Day 40
percent reduction in total lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Percent Reduction From Baseline (Day 1) in Total Lesions at Day 4032.5 ± 32.234.0 ± 27.150.2 ± 27.227.8 ± 31.8
SecondaryNon-Inflammatory Lesion Count at Baseline (Day 1) and Day 40

Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.

Time frame:
Baseline (Day 1), and Day 40
Reported as:
Mean · lesion count
Non-Inflammatory Lesion Count at Baseline (Day 1) and Day 40
lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Baseline (Day 1)21.1 ± 9.521.8 ± 10.719.6 ± 14.119.6 ± 13.6
Day 4016.2 ± 13.116.9 ± 12.713.0 ± 12.016.0 ± 14.1
SecondaryPercent Reduction From Baseline in Non-Inflammatory Lesion at Day 40

Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.

Time frame:
Baseline (Day 1), and Day 40
Reported as:
Mean · percent reduction of lesion count
Percent Reduction From Baseline in Non-Inflammatory Lesion at Day 40
percent reduction of lesion countCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Percent Reduction From Baseline in Non-Inflammatory Lesion at Day 4027.8 ± 39.421.3 ± 42.036.9 ± 36.111.7 ± 48.6
SecondaryNumber of Participants Reported for Investigator's Preference on a 5-Point Scale at Day 40

The Investigator gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.

Time frame:
Day 40
Reported as:
Count of participants · Participants
Number of Participants Reported for Investigator's Preference on a 5-Point Scale at Day 40
ParticipantsGroup I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its Vehicle
Day 40 (Active much better than Vehicle)04
Day 40 (Active better than Vehicle)167
Day 40 (No clinical difference between Active and Vehicle)166
Day 40 (Vehicle better than Active)144
Day 40 (Vehicle much better than Active)10
SecondaryNumber of Participants Reported for Participant's Preference on 5-Point Scale at Day 40

The participants gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.

Time frame:
Day 40
Reported as:
Count of participants · Participants
Number of Participants Reported for Participant's Preference on 5-Point Scale at Day 40
ParticipantsGroup I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its Vehicle
Day 40 (Active much better than Vehicle)22
Day 40 (Active better than Vehicle)1111
Day 40 (No clinical difference between Active and Vehicle)154
Day 40 (Vehicle better than Active)163
Day 40 (Vehicle much better than Active)31
SecondaryNumber of Participants With Adverse Events (AEs)

AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
From start of study up to follow up (Week 7)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsGroup I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its Vehicle
Number of Participants With Adverse Events (AEs)3214
SecondaryNumber of Participants Reported Worst Local Tolerability Score on Treated Areas (Face and Ear) From Day 1 to Follow up (Week 7)

Signs and symptoms of local cutaneous irritation(local tolerability \[erythema, scaling, dryness, stinging/burning, pruritus\]) were evaluated on all treated areas (face and behind ears if applicable) every day from Day 1 up to follow-up (Week 7) using a 4-point scale of None (0), Mild (1), Moderate (2), or Severe (3). Number of participants reported worst local tolerability score on treated areas from Day 1 to follow up (Week 7) was reported.

Time frame:
From Day 1 up Follow up (Week 7)
Reported as:
Count of participants · Participants
Number of Participants Reported Worst Local Tolerability Score on Treated Areas (Face and Ear) From Day 1 to Follow up (Week 7)
ParticipantsCD5024 1% CreamCD5024 1% Cream Matched PlaceboAdapalene Benzoyl PeroxydeAdapalene Benzoyl Peroxyde Matched Placebo
Face: Erythema: 0-None3738815
Face: Erythema: 1-Mild99116
Face: Erythema: 2-Moderate2131
Face: Scaling/Desquamation: 0-None3838516
Face: Scaling/Desquamation: 1-Mild1010135
Face: Scaling/Desquamation: 2- Moderate0041
Face: Dryness: 0-None3837410
Face: Dryness: 1-Mild10111312
Face: Dryness: 2-Moderate0050
Face: Stinging/Burning: 0-None4443817
Face: Stinging/Burning: 1-Mild3485
Face: Stinging/Burning: 2-Moderate1160
Ear: Erythema: 0-None2020811
Ear: Erythema: 1-Mild2220
Ear: Erythema: 2-Moderate0010
Ear: Scaling/Desquamation: 0-None2222711
Ear: Scaling/Desquamation: 1-Mild0030
Ear: Scaling/Desquamation: 2-Moderate0010
Ear: Dryness: 0-None2222710
Ear: Dryness: 1-Mild0031
Ear: Dryness: 2-Moderate0010
Ear: Stinging/Burning: 0-None2222811
Ear: Stinging/Burning: 1-Mild0020
Ear: Stinging/Burning: 2-Moderate0010

Adverse events

Collected over From start of study up to follow up (Week 7). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group I: CD5024 Cream Versus Its Vehicle0/48 (0%)0/48 (0%)32/48 (66.7%)
Group II: Epiduo Gel Versus Its Vehicle0/22 (0%)0/22 (0%)11/22 (50%)
Most frequent other events
Most frequent other events
EventGroup I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its Vehicle
NasopharyngitisInfections and infestations14/484/22
HeadacheNervous system disorders13/485/22
PruritusSkin and subcutaneous tissue disorders0/482/22
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/480/22
Abdominal painGastrointestinal disorders3/480/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its VehicleTotal
Mean23.3 ± 4.723.4 ± 4.423.3 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)Group I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its VehicleTotal
Female341448
Male14822
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its VehicleTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American246
White461460
More than one race000
Unknown or Not Reported022
Number of inflammatory lesions
Number of inflammatory lesions(Lesion Count)Group I: CD5024 Cream Versus Its VehicleGroup II: Epiduo Gel Versus Its VehicleTotal
Mean34.0 ± 11.634.2 ± 15.134.0 ± 12.7
08

Study locations

7 sites
  • Galderma Investigational Site (# 8060)
    Windsor, Ontario N8W 5L7, Canada
  • Galderma Investigational site
    Montreal, Quebec, Canada
  • Galderma investigational site
    Nantes, France
  • Galderma investigational site
    Nice, France
  • Galderma investigational site
    Berlin, Germany
  • Galderma investigational site
    Bochum, Germany
  • Galderma investigational site
    Munster, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Nov 2016, 6 months.

Results were first posted in Dec 2020, 4 years 1 month after primary completion.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Jan 27, 2017
StartActual
Apr 25, 2016
Primary completionActual
Nov 2, 2016
CompletionActual
Nov 2, 2016
Results first posted
Dec 11, 2020
Last update
Dec 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03034460
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jan 27, 2017
Start date
Apr 25, 2016
Primary completion
Nov 2, 2016
Completion
Nov 2, 2016
Results posted
Dec 11, 2020
Last update
Dec 11, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion